



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/54	A2	(11) International Publication Number: WO 00/23471 (43) International Publication Date: 27 April 2000 (27.04.00)
(21) International Application Number: PCT/EP99/07800 (22) International Filing Date: 6 October 1999 (06.10.99) (30) Priority Data: 98203529.7 20 October 1998 (20.10.98) EP (71) Applicant (for all designated States except US): VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECH- NOLOGIE VZW [BE/BE]; Rijvisschestraat 120, B-9052 Zwijnaarde (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): STEIDLER, Lothar [BE/BE]; Bokslaarstraat 41, B-9160 Lokeren (BE). REMAUT, Erik, Rene [BE/BE]; Bergstraat 7, B-9921 Vinderhoute (BE). FIERS, Walter [BE/BE]; Beukendreef 3, B-9070 Destelbergen (BE). (74) Common Representative: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW; Rijviss- chestraat 120, B-9052 Zwijnaarde (BE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: USE OF A CYTOKINE-PRODUCING <i>LACTOCOCCUS</i> STRAIN TO TREAT COLITIS		
(57) Abstract		
<p>The current invention relates to an administraton strategy for the delivery at the intestinal mucosa of cytokines or cytokine antagonists, preferably of acid sensitive anti-inflammatory agents, such as IL10 and/or soluble TNF receptor via the oral route. The prepered feature according to the invention is the inoculation with a suspension of recombinant <i>Lactococcus lactis</i> cells, which had been engineered to produce the respective proteins.</p>		